Inmune Bio Inc.
INMB· Nasdaq
Released Aug 1, 2024, after the close
10-Q filed Aug 1, 2024, 32 days after period end · 0001213900-24-064076
No earnings release is on file for this quarter. Its figures came with the 10-Q.
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $46.00K | $16.00K | $0.00 |
| Net Income | -$9.75M | -$6.50M | -$6.84M | -$6.66M |
| EPS Diluted | -$0.50 |
Inmune Bio Inc. · CIK 1711754 · Engraved from SEC EDGAR
| -$0.36 |
| -$0.38 |
| -$0.44 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.